Ugarte-Gil, M.F.Wojdyla, D.Pons-Estel, G.J.Catoggio L.J.Drenkard, C.Sarano, J.Berbotto, G.A.Borba, E.F.Sato, E.I.Tavares Brenol, J.C.Uribe, O.Ramirez Gómez, L.A.Guibert-Toledano, M.Massardo, L.Cardiel, M.H.Silveira, L.H.Chacón-Diaz, R.Alarcón, G.S.Pons-Estel, B.A.GLADEL6/22/20222022-09-306/22/20222022-09-302017https://doi.org/10.1136/annrheumdis-2017-211814OBJECTIVE: To evaluate disease activity statuses' (DAS') impact on systemic lupus erythematosus (SLE) outcomes.MATERIALS AND METHODS: Four DAS were defined: remission off-therapy: SLE Disease Activity Index (SLEDAI)=0, no prednisone or immunosuppressive drugs (IS); remission on-therapy: SLEDAI=0, prednisone ≤5 mg/day and/or IS (maintenance); low (L) DAS: SLEDAI ≤4, prednisone ≤7.5 mg/day and/or IS (maintenance); non-optimally controlled: SLEDAI >4 and/or prednisone >7.5 mg/day and/or IS (induction). Antimalarials were allowed in all. Predefined outcomes were mortality, new damage (increase of at least one Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI) point) and severe new damage (increase of at least 3 SDI points). Univariable and multivariable Cox regression models were performed to define the impact of DAS, as time-dependent variable, on these outcomes.RESULTS: 1350 patients were included, 79 died during follow-up, 606 presented new and 177 severe new damage. In multivariable analyses, remission (on/off-therapy) was associated with a lower risk of new (HR 0.60; 95% CI 0.43 to 0.85), and of severe new damage (HR 0.32; 95% CI 0.15 to 0.68); low disease activity status (LDAS) was associated with a lower risk of new damage (HR 0.66; 95% CI 0.48 to 0.93) compared with non-optimally controlled. No significant effect on mortality was observed.CONCLUSIONS: Remission was associated with a lower risk of new and severe new damage; LDAS with a lower risk of new damage after adjusting for other damage confounders. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.application/pdfenginfo:eu-repo/semantics/closedAccessBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicineinfo:eu-repo/semantics/article10.1136/annrheumdis-2017-211814http://purl.org/pe-repo/ocde/ford#1.06.03